Clinical pharmacokinetics and administration of established platinum drugs.
about
Pharmacodynamic model for chemotherapy-induced anemia in rats.The interaction of platinum-based drugs with native biologically relevant proteins.Ototoxic Model of Oxaliplatin and Protection from Nicotinamide Adenine DinucleotideEffects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.Creatinine-based equations for the adjustment of drug dosage in an obese population.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrestReview: ototoxic characteristics of platinum antitumor drugs.Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.Investigation on pharmacokinetics, tissue distribution and excretion of a novel platinum anticancer agent in rats by inductively coupled plasma mass spectrometry (ICP-MS).Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity.Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity.Ultrasound image-guided therapy enhances antitumor effect of cisplatin.Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(iv) complex: better stability yet equipotent to the Pt(ii) analogue.Copper(II) and manganese(III) complexes of N'-[(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer.Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels.Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1.Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.Anticancer platinum complexes as non-innocent compounds for catalysis in aqueous media.Platinum compounds and sodium metabolism in children with diencephalic glioma.A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy.Polymeric micelles for targeted tumor therapy of platinum anticancer drugs.Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy.Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer.Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapyLigation of anti-cancer drugs to self-assembling ultrashort peptides by click chemistry for localized therapyCurrent Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
P2860
Q33376775-4EF3A326-A059-41CB-91CD-F62965F690C0Q34439746-E5D8E4BF-99EE-4741-96C3-2FED6667873FQ34556923-F8ECA031-9CB6-4010-9575-8F8A344AA73CQ35925653-3B9A4ACE-4142-4599-B917-2D5335FE3D2DQ36802097-1D2C9A16-4D99-4287-86BC-09DE04E04F54Q36817080-14370FE4-9A10-401E-B6F6-44C11A0D0D4CQ36828315-77DC3516-3A9B-4B77-8DCF-CBD478B995FDQ37112632-E62F8731-7481-4CBE-B809-87C138A0EB6EQ37139330-E1B72872-6DE9-497B-BC48-0E6DAABFED6CQ37599111-5AAD0F35-7EAE-4164-B12C-389B7A8F6EECQ38050374-A16F53ED-0F39-477A-9759-6D87B3D8B846Q38267182-8AFA29D2-16D3-44C7-88B4-C9DC77E5DC09Q38325864-EEAD8511-E602-4FFC-8937-B209E5011F0AQ38641130-653710C9-A516-478C-A99E-4DBCA11737D6Q38886580-16F226C1-E8D0-464E-8FEB-CC5F221EDA63Q39024229-E9535A1E-7CEC-4778-BE86-A363929D063DQ39278942-87B61622-EA4F-4A2B-96BA-6288FAA951BBQ39371239-486B8EBE-EDCA-4FD3-900F-8305AA1DD0FBQ39699429-4E025B36-272F-43BF-94D6-D61372099A8FQ39732972-1A59CE76-9867-4F3F-80B3-CF92AD24DC9FQ40294929-21F9C19E-B91A-4AC7-A8CF-3208BF7BB512Q40677198-BCE705AB-9ECA-4E95-808D-15F94198CA75Q42820956-52427188-37B8-4D24-A07D-3D5C9C646643Q43157204-8CDF422F-9CC1-4C15-A501-5EBADF6337CAQ43196937-48B7FAF1-4B69-4E7D-BE94-4D77C2FC660FQ43443976-53C13084-5970-465C-A636-1EEEC11DF329Q43830000-0BA46980-8D50-4AA0-ABDB-DF7F9E6E73CAQ48408886-E36775B3-3D4E-4981-924C-16B0AAD6FE58Q50960383-97F728E1-E8AA-4C72-8615-BD31F71E81A9Q51554682-61B5AE5E-9ED3-4880-B2F6-01FE9DA58B2CQ52758452-3B23E5C4-3B23-4549-8F6B-5CFC5A0F634CQ53273354-19831703-7D4A-417C-9F04-E9A8D7B148A0Q57280223-72D5BD51-2733-44C2-A473-8D2747E0F141Q58063439-AF3D0218-9E34-4B2F-9A88-59A04351AB95Q58588998-16F9AB6D-6009-4479-8E33-28B1A10EFDC4
P2860
Clinical pharmacokinetics and administration of established platinum drugs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical pharmacokinetics and administration of established platinum drugs.
@ast
Clinical pharmacokinetics and administration of established platinum drugs.
@en
type
label
Clinical pharmacokinetics and administration of established platinum drugs.
@ast
Clinical pharmacokinetics and administration of established platinum drugs.
@en
prefLabel
Clinical pharmacokinetics and administration of established platinum drugs.
@ast
Clinical pharmacokinetics and administration of established platinum drugs.
@en
P2093
P1433
P1476
Clinical pharmacokinetics and administration of established platinum drugs.
@en
P2093
Johnson SW
O'Dwyer PJ
Stevenson JP
P356
10.2165/00003495-200059004-00003
P478
59 Suppl 4
P577
2000-01-01T00:00:00Z
P6179
1048982654